First PIK3CA inhibitor treatment approved, along with diagnostic test.
Recent trial shows greater invasive disease-free survival when treated with Kadcyla , (ado-trastuzumab emtansine)
Women no longer require nine months of contraception post cessation of the drug.
Image Credit: Cancer Health
The FDA has extended the indication for breast cancer drug Ibrance (palbociclib) to male patients.
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.